Clinical Trial Update: An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial of itacitinib in patients with myeloproliferative neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Neoplasms

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: MPN (Myeloproliferative Neoplasms) | Phase 2 | Status: COMPLETED